Thanks for the praise fichman. You're too honest.
The question is how many sales do you think are needed in the future to justify the market cap, which currently sits at around $180M? That's a lot of blue sky to price it at $180M, keeping in mind that it's dropped from $250M over the short term.
Do you think ADAPT will overtake its peers, whether it be: dCELL® No-React® XenoSure®? And will the company have the capacity to take away market share from existing manufacturers that have established sales networks. Some of which provide an abundance of range for vascular products. St Jude, Edwards etc, these are not one product ponies here.
Thanks for the praise fichman. You're too honest. The question...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |